Press release
Hematological Malignancies Drugs Market is on an Upward Growth Curve
According to the latest research by InsightAce Analytic, the global Hematological Malignancies Drugs market is valued at US$ 13.76 Billion in 2021, and it is expected to reach US$ 42.78 Billion by 2030, with a CAGR of 13.7% during a forecast period of 2022-2030.
Request for Sample Pages:
https://www.insightaceanalytic.com/request-sample/1211
Cancers that damage the bone marrow, lymph nodes, and blood are hematological malignancies. The three hematological cancers include myeloma, leukemia, and lymphoma, with lymphoma being the most prevalent kind. The clinical results for blood cancers have been improved by using small molecule inhibitors, monoclonal antibodies, bispecific T cell engagers, antibody-drug conjugates, recombinant immunotoxins, and Chimeric Antigen Receptor T (CAR-T) cells, among other novel targeted therapies.
Increasing R&D efforts to create novel cancer therapies, adoption of precision medicine in the field of hematological malignancies, an increase in the number of drugs approved for the treatment of various types of hematological malignancies, and growing advancements in leukemia and lymphoma targeted therapies are just a few of the factors contributing to the growth of the hematological malignancies drugs market. The demand for this market is anticipated to increase shortly because of the rising prevalence of leukemia and lymphoma diseases. However, it is anticipated that market growth will be constrained in the next years by factors such as expensive treatment and product costs, unfavourable therapeutic side effects, unfavourable medical reimbursement regulations, and safety issues.
Curious about this latest version of the report? Obtain Report Details @ https://www.insightaceanalytic.com/enquiry-before-buying/1211
North America is anticipated to be the major contributor to the Hematological Malignancies Drugs market over the forecast years due to the rising rates of leukemia and lymphoma in this area and the rising R&D spending for cancer therapies. In addition, the Asia Pacific regional market is expected to register significant growth during the estimated period. The market is expected to rise due to rising financing for cancer research, a high incidence of blood cancers, and an increased demand for efficient treatments.
Major market players operating in the Hematological Malignancies Drugs market include
AbbVie Inc., Amgen Inc., Bristol-Myers Squibb Company, F. Hoffmann-La Roche Ltd., Gilead Sciences, Inc., GlaxoSmithKline plc, Immune-Onc Therapeutics, Inc., Johnson & Johnson Services, Inc., Merck & Co., Inc., Novartis International AG, Pfizer Inc., Sanofi S.A., Takeda Pharmaceutical Company Limited, and others.
Recent collaborations and agreements in the market:
• In October 2021, for treating chronic myeloid leukemia (CML), Novartis received the US FDA's approval of Scemblix (asciminib) for two different indications.
• In September 2021, results from the dose-escalation portion of the Phase 1/2 EPCORE NHL-1 first-in-human (FIH) dose-escalation and cohort expansion clinical trial, which evaluated the safety and early efficacy of the investigational therapy epcoritamab (DuoBody-CD3xCD20) in patients with B-cell non-lymphoma Hodgkin's that had relapsed or been resistant to treatment, was released by AbbVie and Genma (B-NHL).
Get Specific Chapter/Information From The Report:
https://www.insightaceanalytic.com/customisation/1211
Market Segments
Global Hematological Malignancies Drugs Market, by Drugs, 2022-2030 (Value US$ Mn)
• Monoclonal Antibodies
o Blincyto (Blinatumomab)
o Besponsa (Inotuzumab Ozogamicin)
o Lumoxiti (Moxetumomab Pasudotox)
o Mylotarg (Gemtuzumab Ozogamicin)
o Opdivo (Nivolumab)
o AiRuiKa (Camrelizumab)
o Tyvyt (Sintilimab)
o Tislelizumab
o Gazyva (Obinutuzumab)
o Zynlonta (Loncastuximab Tesirine-lpyl)
o Darzalex (Daratumumab)
o Blenrep (Belantamab Mafodotin-blmf)
o Keytruda (Pembrolizumab)
o Adcetris (Brentuximab Vedotin)
o Arzerra (Ofatumumab
• CAR-T Cell Therapy
o Tecartus (Brexucabtagene Autoleucel)
o Kymriah (Tisagenlecleucel)
o Yescarta (Axicabtagene Ciloleucel)
o Breyanzi (Lisocabtagene Maraleucel)
o Abecma (Idecabtagene Vicleucel)
Global Hematological Malignancies Drugs Market, by Pipeline Products, 2022-2030 (Value US$ Mn)
• Monoclonal Antibodies
o Teclistamab
o Iomab-B
o Ublituximab
o CS1001
• CAR-T Cell Therapy
o Ciltacabtagene Autoleucel (JNJ-68284528)
Global Hematological Malignancies Drugs Market, by Indications, 2022-2030 (Value US$ Mn)
• Leukemia
o Acute Lymphoblastic Leukemia
o Chronic Lymphoblastic Leukemia
o Acute Myeloid Leukemia
• Lymphoma
o Hodgkin's Lymphoma
o Non-Hodgkin's Lymphoma
• Multiple Myeloma
Global Hematological Malignancies Drugs Market, by Region, 2022-2030 (Value US$ Mn)
• North America
• Europe
• Asia Pacific
• Latin America
• Middle East & Africa
North America Hematological Malignancies Drugs Market, by Country, 2022-2030 (Value US$ Mn)
• U.S.
• Canada
Europe Hematological Malignancies Drugs Market, by Country, 2022-2030 (Value US$ Mn)
• Germany
• France
• Italy
• Spain
• Russia
• Rest of Europe
Asia Pacific Hematological Malignancies Drugs Market, by Country, 2022-2030 (Value US$ Mn)
• India
• China
• Japan
• South Korea
• Australia & New Zealand
Latin America Hematological Malignancies Drugs Market, by Country, 2022-2030 (Value US$ Mn)
• Brazil
• Mexico
• Rest of Latin America
Middle East & Africa Hematological Malignancies Drugs Market, by Country, 2022-2030 (Value US$ Mn)
• GCC Countries
• South Africa
• Rest of Middle East & Africa
Why should buy this report:
To receive a comprehensive analysis of the prospects for the global Hematological Malignancies Drugs market
To receive an industry overview and future trends of the Hematological Malignancies Drugs market
To analyze the Hematological Malignancies Drugs market drivers and challenges
To get information on the Hematological Malignancies Drugs market value (US$ Mn) forecast to 2030
Significant investments, mergers & acquisitions in the Hematological Malignancies Drugs market industry
Get More Information @
https://www.insightaceanalytic.com/report/global-hematological-malignancies-drugs-market--/1211
Contact us:
info@insightaceanalytic.com
InsightAce Analytic Pvt. Ltd.
Visit: www.insightaceanalytic.com
Tel : +1 551 226 6109
Asia: +91 79 72967118
Follow Us on LinkedIn @ bit.ly/2tBXsgS
Follow Us On Facebook @ bit.ly/2H9jnDZ
Twitter: https://twitter.com/Insightace
About Us:
InsightAce Analytic is a market research and consulting firm that enables clients to make strategic decisions. Our qualitative and quantitative market intelligence solutions inform the need for market and competitive intelligence to expand businesses. We help clients gain a competitive advantage by identifying untapped markets, exploring new and competing technologies, segmenting potential markets, and repositioning products. Our expertise is in providing syndicated and custom market intelligence reports with an in-depth analysis with key market insights in a timely and cost-effective manner.https://www.insightaceanalytic.com/images_data/148861653.JPG
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Hematological Malignancies Drugs Market is on an Upward Growth Curve here
News-ID: 3812160 • Views: …
More Releases from Insightace Analytic Pvt Ltd.
Prochlorperazine Maleate Market Size, Share and Trends Analysis Report 2025-2034
InsightAce Analytic Pvt. Ltd. announces the release of a market assessment report on the "Global Prochlorperazine Maleate Market- (By Indication (Nausea and Vomiting Management, Vertigo, Mental Health Disorders (e.g., Schizophrenia)), By Dosage Form (Oral Tablets, Rectal Suppositories, Injectable Formulations), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), By End-User (Hospitals, Clinics, Ambulatory Surgical Centers, Homecare Settings)), Trends, Industry Competition Analysis, Revenue and Forecast To 2034."
According to the latest research…
Primary Cells Market Survey Detailed Analysis and Forecast 2025-2034
InsightAce Analytic Pvt. Ltd. announces the release of a market assessment report on the "Global Primary Cells Market- (By Type (Hematopoietic, Dermatocytes, Hepatocytes, Gastrointestinal, Lung, Renal, Heart, Musculoskeletal), Origin (Human Primary Cells, Animal Primary Cells), End User (Life Science Research Companies, Research Institutes, Others)), Trends, Industry Competition Analysis, Revenue and Forecast To 2034."
According to the latest research by InsightAce Analytic, the Global Primary Cells Market Size is valued at USD…
Predictive Disease Analytics Market expected to Witness Huge Revenue Growth to 2 …
InsightAce Analytic Pvt. Ltd. announces the release of a market assessment report on the "Global Predictive Disease Analytics Market Size, Share & Trends Analysis Report By Component (Hardware, Software & Services), By Deployment (On-premise and Cloud-based), By End-user (Healthcare Providers, Healthcare Payers)- Market Outlook And Industry Analysis 2034"
The Global Predictive Disease Analytics Market is estimated to reach over USD 22.6 Bn by 2034, exhibiting a CAGR of 21.2% during…
Predictive Biomarkers Market Current Scenario with Future Trends Analysis to 203 …
InsightAce Analytic Pvt. Ltd. announces the release of a market assessment report on the "Global Predictive Biomarkers Market- (By Indication (Cancer, Neurological Disorder, Cardiovascular Disorder, Immunological Disorder, Others), By End-Use (Diagnostic Centers, Contract Research Organizations (CROs), Academic Research Institutes, Pharma & Biotech Companies, Others)), Trends, Industry Competition Analysis, Revenue and Forecast To 2034."
According to the latest research by InsightAce Analytic, the Global Predictive Biomarkers Market is expected to grow with…
More Releases for Drugs
Generic Drugs Market Application Anti-Infective Drugs, Anti-Arthritis Drugs, Ant …
Generic drugs are the medications that are developed to be similar to a medicine that is already commercially available in the market with a brand name. The generic drug is similar to the medicine available in terms of dosage, safety and strength, mode of administration, quality and intended use. Due to the similarities, generic drugs are capable of treating various diseases. Generic drugs are most cost effective than the branded…
Cytotoxic Drugs Market Growing Demand for Antimetabolite Drugs
According to Precision Business Insights (PBI), the latest report, the cytotoxic drugs market is expected to be valued at USD 15,927.2 million in 2022 and is poised to grow at a significant CAGR of 2.2% over 2022-2028. The primary drivers of the expansion of the global cytotoxic drugs market include the increasing prevalence of cancer diseases, the increasing use and approval of cytotoxic drugs, and the increasing consumption of alcohol…
Global Antithrombotic Drugs Market | Global Antithrombotic Drugs Industry | Glob …
Antithrombotic drugs are special drugs that help to prevent the formation of thrombus or clot. These drugs are used to reduce the formation of blood clots by reducing the capability of body to form a blood clot. Antithrombotic drugs act by preventing the production of vitamin K in the liver. Anticoagulant, antiplatelet, and thrombolytic agents are different types of antithrombotic agents that act by different clotting processes. Arterial & venous…
Global HIV Drugs Market | Global HIV Drugs Industry | Global HIV Drugs Market Re …
Human immunodeficiency Virus (HIV) could be a chronic and severe sickness which might be transferred from one person to a different through blood-to-blood and sexual contact. it's a deadly disease that attacks immune cells called CD-4 cells, creating body vulnerable to infections and alternative diseases. Over the years, the rising prevalence of HIV sickness worldwide has completely influenced the demand for HIV medicine. HIV medicine facilitate in preventing the multiplication…
Hepatitis Drugs Market by Therapeutics, Diagnostics, Patient, Drugs Policy
The global hepatitis drugs market is growing due to increasing incidences of hepatitis and increasing support from government organizations. In addition, the growing geriatric population, and increasing R&D investments on hepatitis research and drug discovery are also driving the growth of the global hepatitis drugs market.
Access Detailed Report Summary: https://www.psmarketresearch.com/market-analysis/hepatitis-drugs-market
Among the various types, the hepatitis C segment is expected to be the largest segment, and expected to witness the fastest…
Epilepsy Drugs Market by Country, Drugs, Company & Forecast
For More Information:
https://renub-research.blogspot.com/2019/04/the-factors-that-are-driving-global.html
Epilepsy is a chronic disease in which patient’s brain activities become abnormal due to seizures. Seizure is an unexpected rush of electrical activity in the brain. Seizure is categorized by two types - generalized seizures and focal or partial seizures. Generalized seizures affect the whole brain whereas focal or partial seizures affect just one part of the brain. Global epilepsy drugs market is expected to cross US$…
